EHDN plenary meetings

Every second year in September EHDN hosts one of the world’s largest conferences dedicated solely to Huntington’s disease. The meeting is held in conjunction with the European Huntington Association (EHA). The scientific programme includes recent advances in both basic and clinical HD research and attendees have the opportunity to meet experts in the field of HD studies in more informal settings. All EHDN plenary sessions are open to clinicians, scientists, EHA delegates and members of families affected by HD.

In intermedite years a remote meeting is being held, to allow a lively exchange about HD research and the latest news.

Remote Meeting EHDN2021

The 2021 EHDN plenary meeting takes place as a Remote Meeting
September 9th – 11th, 2021.

Further information will be available soon.

Plenary Meeting EHDN2022

The EHDN2022 Plenary Meeting takes place in Bologna,
September 16th – 18th, 2022.
Meeting place:
Bologna Congressi S.r.l.
Piazza della Costituzione, 4/a
40128 Bologna – Italy
Abstract submission:
May – June 2022
May – July 2022

Previous Meeting EHDN2020

virtual bridging EHDN banner

When: September 11, 2020 Time: 14:00 – 18:15 CET

View the programme

Q&A from the meeting (uploaded November 10, 2020)

Recorded sessions:
Welcome and introduction

Anne Rosser
Astri Arnesen
Patrick Weydt

Scientific progress session

  • Chair: Lesley Jones
  • Function of HTT – Frédéric Saudou
  • Somatic expansion of the HTT CAG repeat – Darren Monckton
  • HTT phosphorylation and TBK1 – Hilal Lashuel
  • Oral HTT-lowering therapy – George McAllister
  • Q&A and Discussion
Clinical studies session – PART 1

  • Chair: Jean-Marc Burgunder
  • An Update from the Tominersen Global Clinical Development Programme – Sarah Tabrizi
  • PRECISION HD1 and 2: allele selective targeting of the mutant HTT – Anna Heinzmann
  • Shield-HD – Anne Rosser
  • Prilenia – Bernhard Landwehrmeyer
  • First Human AAV Gene Therapy Clinical Trial in Adults with Early Manifest HD – Ralf Reilmann
Clinical studies session – PART 2

  • Chair: Jean-Marc Burgunder
  • MIG-HD trial – Anne-Catherine Bachoud-Levi
  • HEATED- Huntington’s Equal Access to Effective Drugs – Hugh Rickards
  • Q&A and Discussion
Closing remarks

Bernhard Landwehrmeyer
Anne Rosser